Vestal Point Capital’s Cymabay Therapeutics CBAY Stock Holding History

Vestal Point Capital’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,625,000	Closed	-$38.4M	–	76
2023 Q4	$38.4M	Buy	+1,625,000	New	+$28.9M	4.07%	9

Other funds holding CBAY

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Vestal Point Capital's CBAY Position: Q1 2024 in Review

Vestal Point Capital sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 1,625,000 shares — an estimated $38.4M sold.

Vestal Point Capital first reported a position in CBAY in Q4 2023 and held it in 1 quarter. The position peaked at $38.4M in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

Vestal Point Capital reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
Vestal Point Capital sold 1,625,000 Cymabay Therapeutics shares in Q1 2024, an estimated $38.4M.
Vestal Point Capital first reported a position in Cymabay Therapeutics in Q4 2023 and held it in 1 quarter.
Vestal Point Capital's Cymabay Therapeutics position peaked at $38.4M in Q4 2023.
1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Vestal Point Capital's 13F filing for Q1 2024, filed 14 May 2024.